Literature DB >> 12776203

MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers.

Scott Bader1, Marion Walker, Heather A McQueen, Robert Sellar, Elizabeth Oei, Suzan Wopereis, Yanhua Zhu, Audrey Peter, Adrian P Bird, David J Harrison.   

Abstract

The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5'-DCC 3'-MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776203     DOI: 10.1038/sj.onc.1206574

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex.

Authors:  Anne Y Lai; Paul A Wade
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  The loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits.

Authors:  Andrea M Allan; Xiaomin Liang; Yuping Luo; Changhui Pak; Xuekun Li; Keith E Szulwach; Dahua Chen; Peng Jin; Xinyu Zhao
Journal:  Hum Mol Genet       Date:  2008-04-01       Impact factor: 6.150

5.  Light-regulated and cell-specific methylation of the maize PEPC promoter.

Authors:  Ben J Tolley; Helen Woodfield; Samart Wanchana; Richard Bruskiewich; Julian M Hibberd
Journal:  J Exp Bot       Date:  2011-12-05       Impact factor: 6.992

Review 6.  Epigenetics provides a new generation of oncogenes and tumour-suppressor genes.

Authors:  M Esteller
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

Review 7.  An epigenetic regulator: methyl-CpG-binding domain protein 1 (MBD1).

Authors:  Lu Li; Bi-Feng Chen; Wai-Yee Chan
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

Review 8.  Emerging Molecular and Biological Functions of MBD2, a Reader of DNA Methylation.

Authors:  Kathleen H Wood; Zhaolan Zhou
Journal:  Front Genet       Date:  2016-05-26       Impact factor: 4.599

9.  Screening of Tumor Suppressor Genes in Metastatic Colorectal Cancer.

Authors:  Lu Qi; Yanqing Ding
Journal:  Biomed Res Int       Date:  2017-04-04       Impact factor: 3.411

10.  Epigenetics and colorectal cancer pathogenesis.

Authors:  Kankana Bardhan; Kebin Liu
Journal:  Cancers (Basel)       Date:  2013-06-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.